Gourt > Health > Pharmacy > Drugs and Medications > P > Pravastatin
In medicine and pharmacology, pravastatin (Pravachol® or Selektine®) is a member of the drug class of statins, used for lowering cholesterol and preventing cardiovascular disease.
Pravastatin was identified originally in a mold called Nocardia autotrophica by researchers of the Sankyo Pharma Inc. It is presently being marketed outside Japan by the pharmaceutical company Bristol-Myers Squibb.
The U.S. Food and Drug Administration approved a generic version of Pravastatin for sale in the United States for the first time on April 24, 2006. Generic Pravastatin Sodium Tablets (10mg, 20mg and 40mg) are manufactured by TEVA Pharmaceuticals in Kfar Sava, Israel. FDA Press Release
More on [ Pravastatin ]
Lipid Lowering Agents :: Drugs and Medications
WL Issued to Amrex Zetron Inc
FDA Tue, 14 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Amrex Zetron Inc on 14 Apr 2009 by Los Angeles District Office
WL Issued to Coast Institutional Review Board
FDA Tue, 14 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research
WL Issued to Branitz, Bruce, MD
FDA Thu, 09 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research
WL Issued to Cote, Charles J., MD
FDA Mon, 02 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Cote, Charles J., MD on 02 Mar 2009 by Center for Drug Evaluation and Research
WL Issued to Genzyme Corporation
FDA Fri, 27 Feb 2009 00:00:00 -0400
FDA Warning Letter Issued to Genzyme Corporation on 27 Feb 2009 by New England District Office
WL Issued to Hammill Manufacturing Company
FDA Tue, 06 Jan 2009 00:00:00 -0400
FDA Warning Letter Issued to Hammill Manufacturing Company on 06 Jan 2009 by Cincinnati District Office
CFDA: FDA Latest Drug GCP Warning Letters
WL Issued to Coast Institutional Review Board
FDA Tue, 14 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research
WL Issued to Branitz, Bruce, MD
FDA Thu, 09 Apr 2009 00:00:00 -0400
FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research
WL Issued to Bukowski, Ronald M, MD
FDA Mon, 30 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Bukowski, Ronald M, MD on 30 Mar 2009 by Center for Drug Evaluation and Research
WL Issued to Youabian, Inc
FDA Tue, 17 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Youabian, Inc on 17 Mar 2009 by Los Angeles District Office
WL Issued to Provena St. Joseph's Medical Center IRB
FDA Thu, 12 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Provena St. Joseph's Medical Center IRB on 12 Mar 2009 by Center for Biologics Evaluation and Research
WL Issued to Paulson, Daniel M., MD
FDA Wed, 11 Mar 2009 00:00:00 -0400
FDA Warning Letter Issued to Paulson, Daniel M., MD on 11 Mar 2009 by Center for Drug Evaluation and Research
DrugDigest: Pravastatin ( Pravachol ) - Information on dosage, usage, side effects, interactions, and drug comparisons, including generics when available.
eMedicine Health: Pravastatin (Pravachol) - Provides medication description, prescribing information and resources.
Meta Description: [ Pravachol is the brand name. Pravastatin is the generic name. Pravachol is the most studied statin (cholesterol-lowering drug) in clinical trials. It is used to decrease LDL cholesterol and triglyceride ... ]
Pravachol - What you should know about first heart attack prevention and Pravachol. (Prevastatin)
Meta Description: [ Bristol-Myers Squibb is a global pharmaceutical company whose mission is to extend and enhance human life by developing innovative medicines and health care products. ]
